TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03286244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 plus paclitaxel
Description: CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles.
Study: NCT04391101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: 400-500ml convalescent plasma
Study: NCT01677936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisins
Description: 1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snacks
Description: 100 calorie snack packs will be administered to the subjects in the snack group
Study: NCT03967704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Life quality evaluation
Description: As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss \> 2 cm and/or pain.
Study: NCT00502229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate, metformin, highly purified urinary FSH
Study: NCT00283322

Intervention type: OTHER
Intervention: blood samples (2)
Description: Two blood samples were obtained from patients and tested for heparin antibodies.

Intervention type: OTHER
Intervention: blood samples (2)
Description: Two blood samples were obtained from patients and tested for heparin antibodies.

Intervention type: OTHER
Intervention: blood samples (2)
Description: Two blood samples were obtained from patients and tested for heparin antibodies.
Study: NCT04127955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior based Physical Activity Intervention
Description: Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial.
Study: NCT04316130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uincare Homeplus
Description: Interactive digital healthcare system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Brochure
Study: NCT02503475

Intervention type: OTHER
Group type: OTHER
Intervention: Real-Time fMRI
Description: Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT or MBSR
Description: CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.

Intervention type: DEVICE
Group type: OTHER
Intervention: Acupuncture
Description: Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
Study: NCT03913897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction methods
Description: The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction methods
Description: The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
Study: NCT04053413

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
Study: NCT02138292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (2mg)/Digoxin (.25mg)
Description: 1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks.
Study: NCT03728023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205
Description: SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose in SAD and once daily for 14 days
Study: NCT03150355

Intervention type: PROCEDURE
Intervention: Arthroplasty or open reduction and internal fixation
Description: fixation of proximal femoral fractures or replacement with prosthesis

Intervention type: PROCEDURE
Intervention: Arthroplasty or open reduction and internal fixation
Description: fixation of proximal femoral fractures or replacement with prosthesis
Study: NCT03409991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opening Doors
Description: This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
Study: NCT04451187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 1
Description: Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 1
Description: Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.
Study: NCT04451187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 1
Description: Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 1
Description: Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 2
Description: Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 2
Description: Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 2
Description: Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant Dose 2
Description: Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
Study: NCT03872362

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images
Study: NCT01206127

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative positioning: Bed rest
Description: Patients in this group should be lying down facing up 2 hours postoperatively
Study: NCT02099175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - Patients needing curative neck irradiation
Description: LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively.
Study: NCT04584151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional analgesia
Description: Insertion of bilateral ESP catheters
Study: NCT00300274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil supplied as 500 mg tablets.
Study: NCT03872362

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images
Study: NCT03915886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-0440
Description: JNJ-0440 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-0440
Description: JNJ-0440 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-0440
Description: JNJ-0440 tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets will be administered orally.
Study: NCT03619616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 7.5 mg
Description: ZSP1603 capsule administered orally once daily under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 12.5 mg
Description: ZSP1603 capsule administered orally once daily in the fasting state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 12.5mg
Description: Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 25 mg
Description: ZSP1603 capsule administered orally once daily under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 25mg
Description: Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 50 mg
Description: ZSP1603 capsule administered orally once daily under fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50mg
Description: Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
Study: NCT04191954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fasudil eye drops (concentration 0.5 percent)
Description: receive Fasudil eye drops (concentration 0.5 percent) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: receive artificial tears drop
Description: receive artificial tears drop with the same frequency
Study: NCT04308330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
Study: NCT01304849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Description: Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm
Study: NCT04540497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Inebilizumab is a monoclonal antibody that depletes B cells.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02425449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
Study: NCT02899000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel
Description: Topical acne therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral doxycycline hyclate
Description: Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
Study: NCT02957812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made Foot Orthotics (CFO)
Description: Provides longitudinal arch support
Study: NCT04575493

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crano-cure
Description: Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 500 mg
Description: Being a standard drug as antibiotic and will be used in Control group.
Study: NCT04065932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165-01
Description: Participants will receive BMS- 986165 -01 in prototype formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165-01
Description: Participants will receive BMS- 986165 -01 in prototype formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165-01
Description: Participants will receive BMS- 986165 -01 in prototype formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165-01
Description: Participants will receive BMS- 986165 -01 in prototype formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165-01
Description: Participants will receive BMS- 986165 -01 in prototype formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Participants will receive BMS-986165 in tablet form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
Study: NCT02716220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Implanttaion fo the DREAMS 2G Scaffold
Study: NCT03483519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
Study: NCT06076980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: compare the hemodynamic parameters of paracetamol as bolus versus extended infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: compare the hemodynamic parameters of paracetamol as bolus versus extended infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: as placebo
Study: NCT04947072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
Study: NCT01580293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027
Study: NCT00812617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral water (Hita, Oita, Japan)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral water (Aso-gun, Kumamoto, Japan)